小沟结合剂作为新型抗分枝杆菌药物的评估及非离子表面活性剂囊泡递送系统的增效作用
该研究评估了96种小沟结合剂(MGB)化合物对结核分枝杆菌(Mtb)的杀菌活性,筛选出7个MIC99在0.39–1.56 μM的候选化合物,其中MGB-362和MGB-364对临床Beijing株HN878具有细胞内杀菌活性且无毒性;将MGB封装入非离子表面活性剂囊泡(NIV)后,细胞内抗分枝杆菌活性分别提高1.6倍和2.1倍,与利福平单药效果相似。
要点
- MGB化合物对Mtb H37Rv的MIC99为0.39–1.56 μM,筛选出7个候选。
- MGB-362和MGB-364对临床株HN878的MIC50分别为4.09和4.19 μM且无毒性。
- NIV封装使MGB细胞内活性提高1.6–2.1倍,与利福平相当。
核心结论
- MGB化合物是一类有前景的新型抗结核药物/化学实体。
- NIV递送系统可增强MGB对细胞内Mtb感染的疗效,值得进一步临床前评估。
研究设计与样本
- 研究使用96种MGB化合物,通过H37Rv-GFP微孔板法筛选对Mtb的杀菌活性。
- 对候选化合物在骨髓来源巨噬细胞中评估对临床Beijing株HN878的细胞内杀菌活性,采用标准菌落形成单位计数。
- 细胞活力通过CellTiter-Blue法评估;所选MGB封装入非离子表面活性剂囊泡(NIV)进行递送系统评价。
主要发现
- H37Rv-GFP筛选得到7个候选化合物,MIC99在0.39至1.56 μM之间。
- MGB-362和MGB-364对Mtb HN878的细胞内MIC50分别为4.09和4.19 μM,且无毒性。
- 封装入NIV后,细胞内抗分枝杆菌活性分别提高1.6倍和2.1倍,与利福平单药效果相似。
关键数值与推荐
- MGB候选化合物对Mtb H37Rv的MIC99范围为0.39–1.56 μM。
- MGB-362对Mtb HN878的细胞内MIC50为4.09 μM。
- MGB-364对Mtb HN878的细胞内MIC50为4.19 μM。
- NIV封装使MGB-362和MGB-364的细胞内活性分别提高1.6倍和2.1倍。
临床怎么用
- MGB化合物可作为抗结核新药研发的候选方向。
- NIV递送系统可能改善MGB对细胞内Mtb感染的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The slow development of major advances in drug discovery for the treatment of Mycobacterium tuberculosis (Mtb) infection suggests a compelling need for evaluation of more effective drug therapies against TB. New classes of drugs are constantly being evaluated for anti-mycobacterial activity with currently a very limited number of new drugs approved for TB treatment. Minor groove binders (MGBs) have previously revealed promising antimicrobial activity against various infectious agents; however, they have not yet been screened against Mtb. METHODS: The mycobactericidal activity of 96 MGB compounds against Mtb was determined using an H37Rv-GFP microplate assay. MGB hits were screened for their intracellular mycobactericidal efficacy against the clinical Beijing Mtb strain HN878 in bone-marrow-derived macrophages using standard cfu counting. Cell viability was assessed by CellTiter-Blue assays. Selected MGBs were encapsulated into non-ionic surfactant vesicles (NIVs) for drug delivery system evaluation. RESULTS: H37Rv-GFP screening yielded a hit-list of seven compounds at an MIC99 of between 0.39 and 1.56 μM. MGB-362 and MGB-364 displayed intracellular mycobactericidal activity against Mtb HN878 at an MIC50 of 4.09 and 4.19 μM, respectively, whilst being non-toxic. Subsequent encapsulation into NIVs demonstrated a 1.6- and 2.1-fold increased intracellular mycobacterial activity, similar to that of rifampicin when compared with MGB-alone formulation. CONCLUSIONS: MGB anti-mycobacterial activities together with non-toxic properties indicate that MGB compounds constitute an important new class of drug/chemical entity, which holds promise in future anti-TB therapy. Furthermore, the ability of NIVs to better deliver entrapped MGB compounds to an intracellular Mtb infection suggests further preclinical evaluation is warranted.
引用
- Hlaka L, Rosslee MJ, Ozturk M, et al. Evaluation of minor groove binders (MGBs) as novel anti-mycobacterial agents and the effect of using non-ionic surfactant vesicles as a delivery system to improve their efficacy. J Antimicrob Chemother. 2017. PMID: 28961913. doi:10.1093/jac/dkx326
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。